Ossianix Receives Grant from The Michael J. Fox Foundation to Advance TXP1 Brain Shuttle for Delivering TrkB Agonist Antibody in Parkinson’s Disease Therapy by PS, 09 Jan, 2025 Stevenage, UK – 9 January 2025 – Ossianix Inc., an antibody discovery and engineering company with a CNS focus, has been awarded…
Read More